Please use this identifier to cite or link to this item:
|Title:||MyoCell, a cell-based, autologous skeletal myoblast therapy for the treatment of cardiovascular diseases|
|Source:||Haider, H.Kh., Lei, Y., Ashraf, M. (2008-12). MyoCell, a cell-based, autologous skeletal myoblast therapy for the treatment of cardiovascular diseases. Current Opinion in Molecular Therapeutics 10 (6) : 611-621. ScholarBank@NUS Repository.|
|Abstract:||Cell therapy is fast emerging as a potential therapeutic option in cardiovascular therapeutics. Because of their inherent myogenic differentiation potential, skeletal myoblasts (SkMs) have been extensively assessed in preclinical and clinical studies for their feasibility, safety and effectiveness for myocardial repair. Bioheart Inc is developing MyoCell, autologous SkMs delivered by MyoCath and MyoStar catheter delivery systems, for the treatment of cardiovascular diseases such as myocardial infarction and congestive heart failure. MyoCell is undergoing phase II/III clinical development and has so far demonstrated safety and efficacy, including improvements in cardiac function in phase I/II clinical trials. © Thomson Reuters (Scientific) Ltd.|
|Source Title:||Current Opinion in Molecular Therapeutics|
|Appears in Collections:||Staff Publications|
Show full item record
Files in This Item:
There are no files associated with this item.
checked on Jan 14, 2018
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.